^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    epiHERA™

    Company:
    INEX Innovate
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    2ms
    Prospective Evaluation of Cervical Scrapings CDO1 and CELF4 Methylation (epiHERA®) Assay in Detection of Endometrial Cancer. (PubMed, Cancers (Basel))
    It can act as a triage to reduce invasive endometrial assessment. All false-positive cases were related to neoplastic processes in the genital tract, indicating that it may be useful for detecting cancer early, before histological change is evident.
    Journal
    |
    CELF4 (CUGBP Elav-Like Family Member 4)
    |
    epiHERA™
    over2years
    INEX Innovate launches epiHERA®, a step forward in early endometrial cancer detection, at the Singapore International Congress of Obstetrics and Gynaecology (BioSpace)
    "INEX Innovate...is pleased to announce the launch of epiHERA® the company’s early endometrial cancer detection technology. epiHERA® was unveiled at the esteemed 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG), held from August 25th to 27th."
    Launch
    |
    epiHERA™
    over2years
    Validation of epiHERA, a Minimally Invasive PCR Screening Tool for Hypermethylated CDO1/CELF4 Genes Associated with Endometrial Cancer (Selected for Oral Presentation, O-03-02) (AMP Europe 2023)
    The replacement of biopsy sample acquisition through dilation and curettage with the minimally invasive endometrial swabs using Thinprep, and the high diagnostic accuracy, poise epiHERA as a promising molecular tool for the screening of endometrial cancer.
    CDO1 (Cysteine Dioxygenase Type 1) • CELF4 (CUGBP Elav-Like Family Member 4)
    |
    epiHERA™
    over2years
    Inex Innovate to launch PCR-based endometrial cancer detection test (Genomeweb)
    "Inex Innovate of Singapore plans to launch a PCR-based endometrial cancer detection test this summer, following interim results from a clinical study with researchers at the Chinese University of Hong Kong that were presented here at the Association of Molecular Pathology 2023 Europe Congress this week."
    Launch
    |
    epiHERA™